MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03804nam a22005177a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
211101s20212021 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
1078-0432 |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
34400413 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC. |
| 251 ## - Source |
|---|
| Source |
Clinical Cancer Research. 27(21):5810-5817, 2021 11 01. |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
Clin Cancer Res. 27(21):5810-5817, 2021 11 01. |
| 252 ## - Abbreviated Source |
|---|
| Former abbreviated source |
Clin Cancer Res. 2021 Aug 16 |
| 253 ## - Journal Name |
|---|
| Journal name |
Clinical cancer research : an official journal of the American Association for Cancer Research |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2021 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Manufacturer |
FY2022 |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
|---|
| Publication status |
ppublish |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2021-11-01 |
| 268 ## - Previous citation |
|---|
| -- |
Clinical Cancer Research. 2021 Aug 16 |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
CONCLUSIONS: FASN is commonly expressed in early TNBC. Omeprazole can be safely administered in doses that inhibit FASN. The addition of omeprazole to neoadjuvant AC-T yields a promising pCR rate that needs further confirmation in randomized studies. Copyright (c)2021 American Association for Cancer Research. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
PATIENTS AND METHODS: Patients with operable TNBC were enrolled in this single-arm phase II study. Patients began omeprazole 80 mg orally twice daily for 4-7 days prior to neoadjuvant anthracycline-taxane-based chemotherapy (AC-T) and continued until surgery. The primary endpoint was pathologic complete response (pCR) in patients with baseline FASN overexpression (FASN+). Secondary endpoints included pCR in all surgery patients, change in FASN expression, enzyme activity, and downstream protein expression after omeprazole monotherapy, safety, and limited omeprazole pharmacokinetics. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
PURPOSE: Fatty acid synthase (FASN) is overexpressed in 70% of operable triple-negative breast cancer (TNBC) and is associated with poor prognosis. Proton pump inhibitors selectively inhibit FASN activity and induce apoptosis in TNBC cell lines. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
RESULTS: Forty-two patients were recruited with a median age of 51 years (28-72). Most patients had >=cT2 (33, 79%) and >=N1 (22, 52%) disease. FASN overexpression prior to AC-T was identified in 29 of 34 (85%) evaluable samples. The pCR rate was 72.4% [95% confidence interval (CI), 52.8-87.3] in FASN+ patients and 74.4% (95% CI, 57.9-87.0) in all surgery patients. Peak omeprazole concentration was significantly higher than the IC50 for FASN inhibition observed in preclinical testing; FASN expression significantly decreased with omeprazole monotherapy [mean change 0.12 (SD, 0.25); P = 0.02]. Omeprazole was well tolerated with no grade >= 3 toxicities. |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Fatty Acid Synthases/ai [Antagonists & Inhibitors] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Neoadjuvant Therapy |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Omeprazole/tu [Therapeutic Use] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Triple Negative Breast Neoplasms/dt [Drug Therapy] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Adult |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Aged |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Female |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Humans |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Middle Aged |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Omeprazole/pd [Pharmacology] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Treatment Outcome |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
|---|
| Institution |
MedStar Franklin Square Medical Center |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
|---|
| Institution |
Washington Cancer Institute |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Gallagher, Christopher |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Lynce, Filipa |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Ottaviano, Yvonne |
| 790 ## - Authors |
|---|
| All authors |
Althouse SK, Ballinger TJ, Bauchle A, Dong Z, Gallagher C, Liu JY, Lynce F, Masters AR, Miller KD, Ottaviano YL, Perkins SM, Sardesai SD, Schneider BP, Storniolo AM, Stratford RE Jr, Thomas A, Zhang JT |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.1158/1078-0432.CCR-21-0493">https://dx.doi.org/10.1158/1078-0432.CCR-21-0493</a> |
| Public note |
https://dx.doi.org/10.1158/1078-0432.CCR-21-0493 |
| 858 ## - ORCID |
|---|
| ORCID text |
Gallagher, Christopher |
| Orcid |
<a href="https://orcid.org/0000-0002-3846-5052">https://orcid.org/0000-0002-3846-5052</a> |
| Name |
https://orcid.org/0000-0002-3846-5052 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
